Boston Scientific BSX

Reference table

1. What the price did, and what the business did

The two series have separated and the separation is the whole thesis.

The business decelerated from roughly 19% to 7%. The share price fell 53%. Those two facts are not proportionate, and the gap between them is what this dive is about.

The June quarter by business, filing-verified from the 10-Q filed 2026-08-03 ($M):

And the six-month figures, which reveal the sequential shape:

Read the two tables together and the deceleration is inside Cardiovascular. The segment grew 9.4% organic across six months and 7.8% in the June quarter alone — which implies roughly 11% in the March quarter. Cardiovascular is 66.6% of the company, and it slowed about three points sequentially. That is the number the market has been repricing since 4 February, and it is the number the lawsuit is about.

Urology is the other soft spot and the company explains it: "reported net sales growth was relatively flat, primarily driven by underperformance in our stone franchise as a result of volume-based-procurement in China, and commercial disruption in our sacral neuromodulation franchise." $684M growing 0.8% organic.

Neuromodulation is the bright spot at +12.2% organic, benefiting from the Axonics acquisition closed in November 2024, and Endoscopy at +7.0% is led by the AXIOS stent and delivery system.

2. The securities class action — the overhang, quoted in full

This is the most important disclosure in the file and it appears in no vendor field. From the 10-Q's commitments and contingencies note:

> "On March 5, 2026, purported Company shareholder John Rudolph Troike, individually and on behalf of all others similarly situated, filed a putative securities class action complaint in the United States District Court for the District of Massachusetts against the Company and certain current officers stemming from the drop in the Company's stock price on February 4, 2026 following the release of the Company's fourth quarter and full year 2025 results. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on allegedly false and misleading statements concerning the Company's financial guidance and anticipated growth in the U.S. electrophysiology business unit. The complaint seeks, among other relief, unspecified compensatory damages, unspecified equitable relief, and costs and expenses. On May 20, 2026, the Court appointed the Indiana Public Retirement System as lead plaintiff. On July 20, 2026, plaintiffs filed an amended complaint, adding additional named plaintiffs Miami Fire Fighters' and Police Officers' Retirement Trust and Detroit General Retirement System, and additionally alleging violation of Section 20A of the Securities Exchange Act of 1934 against a current officer."

Five observations, stated as facts rather than judgements.

First, this disclosure dates the collapse. The share-price drop occurred on 2026-02-04, on the release of fourth-quarter and full-year 2025 results. The earnings calendar shows that print BEAT: adjusted EPS of $0.80 against a $0.781 estimate. So the stock fell on guidance, not on results — which is exactly what the complaint alleges.

Second, it names the business. "The U.S. electrophysiology business unit." That is the pulsed-field ablation franchise inside Cardiovascular, and it is the business that took Boston Scientific's organic growth from mid-single digits to high teens between 2023 and 2025.

Third, the escalation on 2026-07-20 is material and recent. A Section 20A claim is the insider-trading provision of the Exchange Act: it alleges a defendant traded contemporaneously with the plaintiffs while in possession of material non-public information. It is directed at "a current officer." Two weeks after that amendment, the Executive Vice President and Group President of Cardiology acquired 64,198 shares in the open market — which is worth stating alongside the allegation without drawing a conclusion from it.

Fourth, three public pension funds are now named plaintiffs — Indiana Public Retirement System as lead, plus Miami Fire Fighters' and Police Officers' Retirement Trust and Detroit General Retirement System. Institutional lead plaintiffs are associated with cases that are litigated rather than dropped.

Fifth, and this is the honest quantification: the company has not accrued for it and neither can we. The 10-Q states generally that "Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be reasonably estimated." Securities class actions of this profile at companies of this size have historically settled in the hundreds of millions rather than the billions — against a $73 billion market capitalisation and $4.5 billion of annual operating cash flow. We do not deduct a specific number from fair value; we hold the verdict at Tactical because of it, and we make it the first kill criterion.

One further legal datum for scale: the June-quarter adjusted-EPS bridge contains $76M pre-tax of "Litigation-related net charges/credits", $0.04 per share — the ordinary run-rate of a medical-device company's legal costs and not obviously a reserve for this case.

3. The two corporate actions the payload cannot see

The $2 billion accelerated share repurchase — and the change in policy it represents. From the 8-K filed 2026-05-18:

> "On May 18, 2026, Boston Scientific Corporation... has entered into an accelerated share repurchase ('ASR') agreement with JPMorgan Chase Bank, National Association for $2 billion... of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, the Company will pay the repurchase price and receive common stock with an aggregate value of 80% of the repurchase price based on the closing share price of the Company's common stock as of May 15, 2026: this represents approximately 30.4 million shares based on the May 15, 2026, closing price of $52.68... The final settlement of the ASR is expected to be completed by June 30, 2026. Following completion of the ASR, the Company will have $3 billion remaining available under the share repurchase authorization."

The context that makes this significant is in the payload and easy to miss: cf_a reports commonStockRepurchased of ZERO for FY2023, FY2024 and FY2025. Boston Scientific did not buy back a single share in three years, and pays no dividend — dividendYieldTTM is 0. It has now committed $2 billion at a $52.68 reference and has $3 billion more authorised, on a $73.0 billion market capitalisation. The full $5 billion is 6.8% of the company. A company that has never returned capital starting to do so at a 55% drawdown, at prices above today's, is the clearest management signal in this file.

The 2026 Restructuring Plan. From the 8-K filed 2026-07-27, reporting a board approval of 2026-07-21:

Two qualifications, both from the filings. Management states that "a substantial portion of the savings" is expected to be reinvested in strategic growth initiatives — so the $500 million is a gross figure and the net margin benefit will be smaller. And the 10-K discloses a covenant consequence: "As of December 31, 2025, we had none of the restructuring charge exclusion remaining; no further restructuring charges will be excluded" from the consolidated EBITDA used to test the leverage covenant. So $700-800 million of charges will count against a maximum permitted leverage ratio of 4.50x stepping to 3.75x. At net debt of $12,085M against roughly $5.6-5.9 billion of adjusted EBITDA — about 2.1x — the headroom is ample and this is a note rather than a risk. It is worth recording because it is the kind of covenant detail that only appears in a filing.

4. Balance sheet, margins and cash flow

Filing-verified at 2026-06-30 ($M):

Cash fell $1,426M and debt rose $1,188M in six months, which is the $2 billion accelerated buyback arriving. Net debt of $12,085M against approximately $5.6-5.9 billion of adjusted EBITDA is about 2.1x, comfortably inside the 4.50x covenant (stepping to 3.75x).

Margins are the strongest structural feature and they are holding.

Gross margin expanded 300 basis points year on year to 70.7%. A company whose share price fell 53% while gross margin rose three points is worth a second look, and that is the arithmetic case for this dive.

The June-quarter GAAP-to-adjusted bridge, disclosed in full:

Note the IEEPA tariff refund: an $83 million pre-tax, $77 million after-tax CREDIT that the company EXCLUDES from adjusted earnings — the conservative direction, and the same International Emergency Economic Powers Act refund matter that appears at much larger scale in FedEx's file in this batch. The adjustment totals $0.25 on $0.61, 41% of GAAP EPS, of which $0.14 is intangible amortisation from a decade of acquisitions.

Cash flow:

Capital expenditure of $876M / $790M / $711M matches the 10-K's "Purchases of property, plant and equipment and internal use software" exactly in all three years — a verified-clean capex. capexToDepreciationTTM of 0.640 against $1,368M of depreciation and amortisation is plausible. Free cash flow of $3,658M is a 5.01% yield, and the company returned none of it to shareholders in 2025 — which is precisely what changed on 2026-05-18.

5. Valuation — priced in or room?

At $49.12 (market cap $73.01B, 1,486.4M shares implied):

Estimate coverage is good on revenue and thin on EPS beyond FY2027. 19, 22, 24 and 23 analysts on revenue across the four forward years — the deepest revenue coverage in this batch — but only 14 and 16 on FY2026 and FY2027 EPS, falling to 7 on FY2028 and 2 on FY2029, which is excluded. The FY2027 EPS range is $3.236 to $3.704, a 14.5% spread.

The FY2027 air pocket is the most important thing in this table and it is stated rather than smoothed. Consensus has FY2027 revenue growing 4.4% and adjusted EPS growing 3.9% — the lowest forward growth year of any name in this batch — before reaccelerating to 6.8% and 9.9% in FY2028. A one-year trough followed by reacceleration is what analysts publish when they are modelling a specific, temporary headwind rather than a permanent impairment; it is also what they publish when they have cut the near year and not yet cut the far one. We cannot distinguish those from this file and we say so.

est.ebitdaAvg and est.ebitAvg are fabricated and rejected — the twelfth consecutive file. In every one of the eight years present, ebitdaAvg is exactly 23.196% of revenueAvg and ebitAvg is exactly 15.006%. Worse, in every forward year netIncomeAvg EXCEEDS ebitdaAvg — FY2027 shows net income of $5,040M against EBITDA of $5,168M and EBIT of $3,344M, so net income is 51% above EBIT — which is arithmetically impossible for a taxpaying company with $12.6 billion of debt. All forward valuation uses epsAvg, which verifies: the FY2025 epsAvg of $3.036 sits within 0.5% of the $3.05 the four quarterly releases produced.

Enterprise value — verified clean on net debt, with the usual small NCI omission. enterpriseValueTTM of $85,094.8M less market capitalisation is exactly $12,085M, which is the 2026-06-30 balance sheet's net debt to the dollar: current debt obligations $1,709M plus long-term debt $10,915M less cash $539M. The vendor uses the most recent quarter, uses financial debt only, and does NOT inflate it with operating leases — the cleanest enterprise-value construction in this batch. It omits the $239M of noncontrolling interests. Rebuilt: $85,334M, 0.28% above the vendor's figure. This is the fifth consecutive batch in which the NCI-omission check has fired, and BSX's is the smallest instance.

5a. What today's price assumes (the inversion)

At $49.12 — 14.9x FY2026 consensus adjusted EPS and 14.3x FY2027 — the price embeds:

• Adjusted EPS of $3.303 in FY2026. (Consensus, 14 analysts.) The first half delivered $1.66 ($0.80 plus $0.86), so the second half needs $1.64 — a slight sequential decline, and the September consensus of $0.80 is consistent with it. This is a low bar and we expect it met.
• Adjusted EPS of only $3.431 in FY2027 — growth of 3.9%. (Consensus, 16 analysts.) The price does not merely accept the deceleration; at 14.3x it assumes the deceleration is permanent. For comparison, a business growing organic revenue 7.0% at a 70.7% gross margin with a $500 million cost programme should compound earnings faster than 3.9% unless something structural has changed.
• The market keeps paying 13-15x forward earnings. (Our number.) This is the most fragile assumption in the price, and it is fragile in the upward direction. Boston Scientific traded above 25x forward earnings for most of the decade to 2025. At 12x FY2027E the stock is $41; at 20x it is $69, which is roughly the consensus target.
• The securities class action costs something and is not existential. (Our derivation; the filing declines to estimate.) Three public pension funds are named plaintiffs and a Section 20A insider-trading count was added on 2026-07-20. Against $73 billion of market capitalisation and $3.66 billion of annual free cash flow, a settlement in the hundreds of millions is absorbable and a multi-billion outcome would not be.
• The $5 billion buyback continues. (Our number, from the disclosed authorisation.) $2 billion is executed and $3 billion remains — 4.1% of the market capitalisation. If the balance is deployed near current prices it adds roughly 4% to per-share earnings with no operating improvement at all.

5b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: adjusted EPS growth (+3.9%, from FY2026E $3.303 to FY2027E $3.431) + multiple EXPANSION (from 14.3x to roughly 17.5x, +22%) + shareholder yield (up to +4.1% if the remaining authorisation is deployed; zero dividend).

We are going to be explicit about the fragile leg, because this bridge is unusual for this programme: the return here is mostly multiple, not earnings. In every other Buy this house has issued, most of the return was earnings growth and the multiple was assumed flat. Here consensus EPS growth is 3.9% and our base requires the market to pay 17.5x instead of 14.3x. That is a re-rating thesis and it is the weakest kind of thesis, and we are naming it as such rather than burying it.

What makes it defensible rather than hopeful, in three specifics. The de-rating has already been extreme — from above 25x to 14.3x, a 43% multiple compression, against a business that decelerated but did not shrink. The company itself is the marginal buyer — $2 billion executed at $52.68 with $3 billion authorised. And the insiders are buying at $45.48, $46.73, $56.49 and $56.68 with no discretionary sales. Three parties with better information than the market — the board, the executives and the balance sheet — are all buying.

What would break it: FY2027 consensus falling further. At $3.10 of FY2027 EPS and 15x, the stock is $46.50 — below today. Watchable number: the FY2027 consensus EPS of $3.431 at each quarterly print.

5c. Variant perception (where we differ, what would surprise)

• Our variant perception is on the multiple, not the earnings, and we say so plainly. Our base of $60 is 12.6% below the street's $68.67 — so we are more cautious than the sell side on price while more constructive than the market on multiple. We use the same consensus EPS rows. What we think the market is mispricing is the assumption that 14.3x is the right multiple for a 70.7%-gross-margin device business growing organic revenue 7.0%, with a cost programme and a buyback, purely because one product line's growth guidance proved too optimistic.
• We think the insider file is materially under-weighted and it is the most information-dense thing in this dive after the lawsuit. Four acquisitions, zero discretionary sales. Two directors bought in the open market at $56.68 and $56.49 in May and one added 5,000 shares at $45.48 on 2026-07-31. And on the same day, the Executive Vice President and Group President of Cardiology acquired 64,198 shares at $46.73 — approximately $3.0 million — taking his disclosed holding from nil to 64,198. That is the executive responsible for the division named in the securities complaint, buying eleven days after the amended complaint was filed. Watchable event: any further Form 4 purchase or sale by that officer.
• We think the FY2027 consensus of 3.9% EPS growth is the crux and we do not claim to know which way it resolves. If it is a trough that reaccelerates to the FY2028 consensus of 9.9%, today's 14.3x is a mistake by the market. If FY2027 is where the estimates are heading rather than where they have stopped, 14.3x is fair. This is a genuine unknown and it is why the position is Tactical and sized to be added to.
• Positive surprise that would force a re-rate: electrophysiology or Cardiovascular organic growth returning above 9% in the September or December quarter; or dismissal of the securities class action; or the remaining $3 billion of buyback executed near current prices; or FY2027 consensus EPS revised UP from $3.431.
• Negative surprise that would break the thesis: Cardiovascular organic growth below 6%; FY2027 consensus EPS revised below $3.20; a securities settlement or reserve above roughly $1 billion; any adverse regulatory development in the electrophysiology franchise; or Urology deteriorating from +0.8% into decline.

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $3.431, low $3.236, high $3.704, 16 analysts), cross-checked on EV/EBITDA and free cash flow.

• Bear ~$39 — 12.1x the FY2027 consensus LOW of $3.236. Cross-checks: 11.8x FY2026E; an enterprise value of $70.1bn against an FY2027 adjusted EBITDA of roughly $6.2bn, 11.3x; 8.5% below the 52-week low of $42.63; 22% below the street's low target of $50. The scenario: the deceleration continues, Cardiovascular growth falls below 6%, FY2027 consensus is cut toward $3.00, the class action produces a large reserve, and a de-rated growth stock finds a value-stock multiple. MINUS 20.6%.
• Base ~$60 — 17.5x the FY2027 consensus MEAN of $3.431. Cross-checks: 18.2x FY2026E; 15.9x FY2028E; an enterprise value of $101.4bn against an FY2027 adjusted EBITDA of roughly $6.7bn (30% margin on consensus revenue), 15.2x; a 4.1% free-cash-flow yield on FY2025's $3,658M. Sensitivity, stated openly: 15x gives $51.5 — 4.8% above spot — and 20x gives $68.6, essentially the street's target. The whole answer is a five-turn band on one estimate row. The scenario: organic growth stabilises near 7%, the $500M cost programme reaches the P&L in part, the remaining $3bn of buyback is deployed, the class action settles at an absorbable number, and the multiple normalises to the low end of medical-device peers rather than back to 25x. +22.2%.
• Bull ~$82 — 22.1x the FY2027 consensus HIGH of $3.704. Cross-checks: 21.7x FY2028E; 24.2% below the 52-week high of $108.14; 19.4% above the street's $68.67 and 26.8% below the street high of $112. The scenario: electrophysiology growth reaccelerates as the comparison base clears, the class action is dismissed, FY2027 estimates are revised up rather than down, the full $5bn buyback completes, and a 70.7%-gross-margin device franchise re-rates back toward — though not to — where it traded before February. +66.9%.

Base is 22.2% above spot; asymmetry roughly 3.25:1 (20.6% down, 66.9% up), with no dividend and up to 4.1% of buyback available. A base above 20% with a payoff ratio above three, on a company whose insiders and treasury are both buying, is what the Buy — Tactical tier exists for. What keeps it out of Core is set out in Section 9.

6. Knowledge base — an empty lane on a $73 billion company that moved 55%

Raw hits: 1. Case-sensitive entity matches: ZERO. Name-level claims: ZERO.

The sweep ran entity terms BSX and Boston Scientific plus free text on boston scientific, pulsed field, farapulse, electrophysiology and watchman across all 52,021 distilled claims.

The single hit, verbatim, and it is not about this company:

> 2024-05-03 · bullish · conviction 70 · horizon: principle · entities: none · channel: michael_levin · skill 1.0 · categories: bioelectricity, electrophysiology

> "Bioelectricity is underappreciated because it exists only in living cells (unlike DNA/proteins studied dead) and demands interdisciplinary physics/computation training biologists lack."

That is a developmental biologist making a claim about the state of a scientific discipline. It matched only on the free-text term electrophysiology, it carries no entities, and it references no company, device, market or investment. It is discarded, and it does not enter any score.

There is no entity match on BSX, Boston Scientific, Farapulse or Watchman anywhere in 52,021 claims.

What this means, stated without softening. No expert in this knowledge base has said anything about Boston Scientific across the six years the store covers — a period in which the shares roughly tripled and then halved, the company completed the Axonics acquisition, pulsed-field ablation became the most-discussed growth story in medical devices, and a securities fraud class action was filed over that same franchise. A $73 billion company whose stock has moved 55% in six months, and the store is silent.

This is the fourteenth void this programme has found and reported honestly, and it is the most conspicuous of them. It is also a directly relevant observation about the store's coverage: the knowledge base is deep on macro, energy, crypto and artificial-intelligence infrastructure and thin to absent on medical devices, which is a gap worth recording rather than papering over.

The practical consequence for this dive: the verdict rests entirely on the filings and the market data. There is no expert-versus-consensus divergence to measure here, so the Buy — Tactical designation is earned on arithmetic and disclosure alone — which is a weaker foundation than a Buy with a corroborating expert lane, and is one of the reasons it is Tactical. Breadth 0, claim count 0, net conviction empty.

7. Data integrity — what we rejected and why

Six findings, and an unusually good enterprise-value construction.

1. Two corporate actions and the securities class action are absent from every vendor field. The $2 billion accelerated share repurchase of 2026-05-18 (part of a $5 billion authorisation, $3 billion remaining), the 2026 Restructuring Plan approved 2026-07-21 ($700-800M of charges, ~$500M of targeted annual savings), and the securities class action filed 2026-03-05 and amended 2026-07-20 to add a Section 20A insider-trading count. cf_a ends at FY2025 and correctly reports zero repurchases in each of FY2023, FY2024 and FY2025 — which makes the omission of the buyback policy change more consequential, not less, because the payload's most recent word on capital return is "none".

2. est.ebitdaAvg and est.ebitAvg are fabricated AND arithmetically impossible — REJECTED. In all eight years present, ebitdaAvg is exactly 23.196% of revenueAvg and ebitAvg is exactly 15.006%. And in every forward year netIncomeAvg EXCEEDS ebitdaAvg: FY2027 shows net income of $5,040M against EBITDA of $5,168M and EBIT of $3,344M — so the block implies net income 51% above operating profit for a company paying tax on $12.6 billion of debt. This trips the documented "ebitAvg > ebitdaAvg is arithmetically impossible" family in an adjacent and equally fatal form. All forward valuation uses epsAvg.

3. bal_a.totalDebt is inflated by $982M and the components do not reconcile line by line — REJECTED. The vendor reports FY2025 shortTermDebt $389M, longTermDebt $11,458M and capitalLeaseObligations $571M, totalling $12,418M. The 10-K's debt table reports current debt obligations $299M and long-term debt $11,436M... total debt $11,436M (current $299M plus long-term $11,137M). The $90M excess in shortTermDebt is exactly the $90M of "Operating lease liabilities in Other current liabilities" disclosed in the lease note. The remaining $892M is not attributable to any single filed line: total operating lease liabilities are $536M ($90M current plus $446M long-term), and finance leases are already inside the filed debt figures per the lease note. So the direction of the error is the documented lease inflation, and part of it reconciles exactly, but the full $982M does not. We report what reconciles and what does not rather than forcing it.

4. bal_a cash at 2025-12-31 disagrees with the filing by $80M. The vendor reports $2,045M; the 10-Q's comparative column reports $1,965M. A 4.1% difference on a cash balance is small in dollars and is the kind of discrepancy that should not exist at all.

5. cf_a FY2023 capitalExpenditure is wrong by $89M while the adjacent field is right. The vendor reports FY2023 capitalExpenditure of $800M and investmentsInPropertyPlantAndEquipment of $711M. The 10-K reports "Purchases of property, plant and equipment and internal use software" of $711M for FY2023. So investmentsInPropertyPlantAndEquipment is correct and capitalExpenditure is 12.5% too high, in the same row, for the same year. FY2025 and FY2024 have the two fields identical and both correct. This is the partial-row corruption class in its purest form: two fields that should agree, one right and one wrong, in one year of a four-year block.

6. seg_prod reports the correct two segments but with a historical break, and seg_geo degrades before FY2018. seg_prod for FY2025 gives Cardiovascular $13,266M and MedSurg $6,829M, summing to $20,095M against revenue of $20,074M — a $21M gap — and reflects the fourth-quarter-2025 reorganisation that "combined our legacy Cardiology and Peripheral Interventions businesses into a single Cardiovascular business". The FY2021 row inconsistently adds a third line, "Cardiac Rhythm Management" $3,293M, which does not appear in adjacent years, and the FY2012 and FY2011 rows use a completely different seven-line taxonomy. seg_geo is correct and complete from FY2018 forward — FY2025 United States $12,864M plus Non-US $7,210M equals $20,074M exactly — but the FY2012 and FY2011 rows contain the placeholder labels "Segment, Geographical, Groups of Countries, Group One" and "Group Two", which are XBRL element names rather than geographies. The recent years are usable and the deep history is not.

VERIFIED CLEAN — recorded because a clean check is a finding, and BSX has the best-constructed enterprise value in this batch.

enterpriseValueTTM is right, current, and free of lease inflation. The $12,085M residual over market capitalisation reconciles exactly to the 2026-06-30 balance sheet — current debt obligations $1,709M plus long-term debt $10,915M less cash $539M — using the most recent quarter rather than the annual balance sheet, and without adding the $536M of operating lease liabilities that inflated totalDebt on five other names in this batch. The only defect is the omission of $239M of noncontrolling interests, which takes the rebuilt figure to $85,334M, 0.28% above the vendor's. In a programme where lease inflation fired on five of twelve names and the largest enterprise-value error in this batch was $12.7 billion, that is a genuinely good construction and it is recorded as such.

capitalExpenditure for FY2025 and FY2024 is exactly correct at $876M and $790M, matching the 10-K's "Purchases of property, plant and equipment and internal use software" to the dollar, making freeCashFlow of $3,658M and the 5.01% recomputed yield sound. The FY2023 field is the exception documented above.

seg_geo is correct and complete for the last eight years, with United States plus Non-US summing exactly to consolidated net sales in every year from FY2018 to FY2025.

Non-equity tripwire — checked and passed. BSX is common stock, NYSE-listed. Price of $49.12 is not par-like; beta is 0.577; there is no dividend; volume was 17.00M shares (~$835M of turnover, the heaviest in this batch); the 52-week band of $42.63 to $108.14 is a 154% range, by far the widest here. This is common equity.

Vendor composite rating — noted, and it is the highest in this batch. The rating block gives A- / 4 overall, with 5 of 5 on discounted cash flow. The discounted-cash-flow sub-score rests on a free-cash-flow figure that is sound (Section 4), so unlike most names in this programme it is not built on a rejected datum. It still adds nothing this dive has not derived directly.

8. Technicals — and the worst entry timing in this batch

• Price $49.12. MINUS 54.6% from the 52-week high of $108.14; +15.2% above the 52-week low of $42.63. Position within the annual range: 10th percentile — the lowest in this batch by a wide margin.
• Above the short average and far below the long one: +6.1% above a 50-day average of $46.29; MINUS 32.4% below a 200-day average of $72.69. The 200-day average is 48% above the 50-day, which is the signature of a collapse that happened fast and recently.
• RSI 82.0 — the most overbought reading in this batch and one of the highest this programme records. MACD +0.39, mildly positive. The stock has risen 15.2% off its low and 6.1% above its 50-day average in a matter of weeks, into an RSI that historically precedes consolidation.
• Current distance from the six-year peak: MINUS 54.6%, identical to the 252-day figure — so the six-year peak falls inside the last twelve months. This company set its all-time high and lost more than half its value inside one year, and the field is working correctly.
• Relative performance is the worst in this batch across every window: 3-month MINUS 13.6% against SPY +7.6%; 6-month MINUS 46.5% against SPY +11.1%; 12-month MINUS 53.4% against SPY +24.3% and QQQ +30.8% — a 77-point twelve-month deficit.
• Beta 0.577, which is the historical figure and plainly does not describe the last six months. A stock that fell 46.5% in six months while the index rose 11.1% was not behaving with a beta of 0.577, and any position sizing that relies on that number is wrong.
• Sentiment: 1 strong buy, 37 buy, 6 hold and ZERO sells across 44 analysts — the most one-sided coverage in this batch. Consensus target $68.67 (+39.8%), median $65, high $112 (+128%), low $50 — 1.8% ABOVE spot. Not one covering analyst has a target below the current price, and the high target of $112 is above the 52-week high — so the coverage universe has not marked down its long-run view even as the stock halved. We treat that as a caution: a research community that has not cut its targets after a 55% decline may be behind the news rather than ahead of it, and the $112 high in particular is almost certainly stale.

Today's move and what it does to the entry

BSX closed 2026-08-04 at $49.12, up 1.42% or $0.69 from $48.43, on 17.00 million shares — the heaviest volume in this batch by a factor of ten against several names. It opened at $48.11, traded $47.98 to $49.21, and closed within 0.2% of the high. The 10-Q was filed 2026-08-03, one day before this dive, and results were released 2026-07-29.

The entry is the weakest part of this recommendation and we are not going to disguise it. RSI at 82.0, six per cent above the 50-day average, after a 15.2% bounce off the low, is a stretched short-term position. Buying a full weight today would be buying the bounce.

What that means operationally, and it is the operative discipline of this dive: take a starter position and reserve the majority of the intended weight for a retest. The 50-day average of $46.29 is 5.8% below the current price and the 52-week low of $42.63 is 13.2% below. A Tactical Buy on a name at RSI 82 is a Buy on the arithmetic and a Wait on the tick, and both halves of that sentence are the recommendation.

9. Insiders — four acquisitions, no discretionary sales, and one that matters

The reading, and it is the strongest insider file in this batch by a wide margin. There is not one open-market sale. Four of the eight rows are acquisitions, three of them coded P-Purchase — the unambiguous open-market buy — and one I-Discretionary, a discretionary transaction inside an employee plan.

The transaction that carries the most information is dated 2026-07-31. Joseph Michael Fitzgerald, Executive Vice President and Group President of Cardiology, acquired 64,198 shares at $46.73 — approximately $3.0 million — taking his disclosed holding from nil to 64,198. Cardiovascular is 66.6% of the company and its electrophysiology unit is the business named in the securities class action. The transaction is dated eleven days after the plaintiffs amended their complaint on 2026-07-20 to add a Section 20A insider-trading count against a current officer. We report the sequence without drawing an inference from it, because the filings do not identify which officer is named and it would be irresponsible to guess. What can be said is that the executive with the best available view of the division at issue committed $3.0 million of his own money at $46.73.

The director purchases are smaller and more straightforward. Edward Ludwig bought 3,580 shares at $56.68 on 2026-05-20 and a further 5,000 at $45.48 on 2026-07-31 — buying more as the price fell, and taking his holding from 21,779 to 30,359, a 39% increase. Cheryl Pegus bought 1,770 shares at $56.49, establishing a position from nil.

One row requires care and we flag it rather than interpreting it. Michael F. Mahoney, Chairman, President and Chief Executive Officer, is recorded on 2026-05-28 with a G-Gift of 386,755 shares and securitiesOwned of 0 afterwards. A G-Gift is a charitable or family transfer and carries no market signal — it is not a sale. The securitiesOwned: 0 field is almost certainly a reporting artefact of a specific holding line (for example, a trust or a particular ownership form) going to zero rather than a statement that the chief executive holds no stock, and the payload gives no way to distinguish the two. We do not treat it as evidence in either direction and we say why.

The chief financial officer's three rows on 2026-07-01 are routine: two M-Exempt option or unit conversions at zero price and one F-InKind tax withholding of 1,010 shares at $43.06 — the mechanically signal-free type.

10. Verdict, kill-criteria and flip conditions

Buy — Tactical.

This is the second Buy this programme has issued and we are going to set out the arithmetic before anything else, because the tier has to be earned rather than defaulted into.

The arithmetic. At $49.12 Boston Scientific trades at 14.9x the FY2026 consensus adjusted EPS of $3.303 and 14.3x FY2027's $3.431, against a decade in which it traded above 25x. Our base fair value of $60 is 22.2% above spot with 3.25:1 asymmetry — the best payoff ratio in this batch. Of 44 covering analysts, one is a strong buy, 37 are buys, six are holds and NONE is a sell; the lowest published target of $50 is above the current price.

The trajectory, from a 10-Q filed one day ago. Net sales $5,442M, +7.5% reported and +7.0% organic. Gross margin 70.7%, up 300 basis points year on year. Operating margin 21.6%, up from 16.2%. Adjusted EPS $0.86 against a $0.835 consensus — the sixth consecutive beat. Cardiovascular +7.8% organic, Neuromodulation +12.2%, Endoscopy +7.0%. Free cash flow of $3,658M in FY2025, a 5.01% yield, with capital expenditure verified exactly correct against the filing.

The capital allocation, which changed decisively this year. A company that repurchased zero shares in 2023, 2024 and 2025 and pays no dividend committed $2 billion to an accelerated repurchase on 2026-05-18 at a $52.68 reference — above today's price — with $3 billion of the $5 billion authorisation remaining, 4.1% of the market capitalisation. And on 2026-07-21 the board approved a restructuring targeting $500 million of annual gross pre-tax expense reduction.

The insiders. Four acquisitions, zero discretionary sales. Director purchases at $56.68, $56.49 and $45.48, and a $3.0 million discretionary acquisition of 64,198 shares at $46.73 by the Executive Vice President and Group President of Cardiology on 2026-07-31.

Why Tactical and not Core, stated as four specific reservations rather than as hedging.

First, the securities class action is live, unquantified and aimed at the thesis. Filed 2026-03-05 over the 2026-02-04 share-price drop, alleging misleading statements about "financial guidance and anticipated growth in the U.S. electrophysiology business unit", with three public pension funds as named plaintiffs and a Section 20A insider-trading count added on 2026-07-20. The company declines to estimate a range of loss and so do we.

Second, the return is mostly multiple rather than earnings, which is the weaker kind of thesis. Consensus FY2027 adjusted EPS growth is 3.9% — the lowest forward year in this batch — and our base requires the market to pay 17.5x instead of 14.3x. In every other Buy this house has issued, most of the return was earnings growth. Here it is not, and that is a real distinction between Tactical and Core.

Third, the knowledge base is empty. Zero entity matches on Boston Scientific in 52,021 claims. There is no expert lane corroborating this and no expert lane contradicting it; the verdict rests on filings and arithmetic alone, which is a thinner foundation than a Buy with a supporting lane.

Fourth, the entry is stretched. RSI 82.0, the price 6.1% above the 50-day average, after a 15.2% bounce off the low.

Pre-registered KILL criteria — what would take this to Watch or Avoid:

• A securities settlement, reserve or judgement above roughly $1 billion, or any expansion of the Section 20A claim to additional officers.
• Cardiovascular organic growth below 6% in the September or December quarter, from 7.8%.
• FY2027 consensus adjusted EPS revised below $3.20, which at 15x puts fair value under $48 — below today's price.
• Total company organic growth below 5%.
• The remaining $3 billion of buyback authorisation left undeployed through the end of 2026, which would say the board no longer thinks the stock is cheap.
• Any adverse regulatory or safety development in the electrophysiology franchise, which would convert a guidance dispute into a product problem.
• Urology deteriorating from +0.8% into outright decline, or a second business joining it below 2%.

Pre-registered UPGRADE conditions — what would take this to Buy — Core:

• Dismissal of the securities class action, or a settlement at a level the company can disclose without qualification.
• FY2027 consensus adjusted EPS revised UP from $3.431, which would confirm the 3.9% growth year is a trough rather than a waypoint.
• Cardiovascular organic growth back above 9%, which is the level that made this a premium-multiple business.
• The full $5 billion buyback completed with a further authorisation.
• Continued insider buying, particularly any further purchase by the Cardiology group president or a first purchase by the chief executive or chief financial officer.
• Name-level knowledge-base coverage appearing at all. At present there is none.

Where BSX fits in the Synthos Framework Portfolio. The healthcare sleeve, entering at 1.0% today with a 3% target, the balance to be added on a retest of the 50-day average at $46.29 or the 52-week low at $42.63, or on confirmation that Cardiovascular growth has stabilised. Sizing note, and it is the operative discipline of this dive: the arithmetic says Buy and the tick says Wait, and the correct expression of both is a small starter with the majority of the weight reserved. A stock that has fallen 54.6% and bounced 15.2% into RSI 82 will very often give a better price within a quarter; a stock at 14.3x forward earnings with insiders and the treasury both buying may not give one at all. A scaled entry is the only position that survives both outcomes. Logged as a tracked Synthos call (Buy — Tactical) as of 2026-08-04 at $49.12, with the fair-value anchors, the kill criteria and the upgrade conditions all gradeable.

Single biggest risk: the securities class action. Filed 2026-03-05 in the District of Massachusetts over "the drop in the Company's stock price on February 4, 2026", alleging violations of Sections 10(b) and 20(a) based on "allegedly false and misleading statements concerning the Company's financial guidance and anticipated growth in the U.S. electrophysiology business unit"; lead plaintiff Indiana Public Retirement System appointed 2026-05-20; amended 2026-07-20 to add two further public pension funds and a Section 20A insider-trading claim against a current officer. The company states that a range of loss cannot be reasonably estimated, and this dive does not estimate one either. What can be said about scale: market capitalisation is $73.0 billion, annual free cash flow is $3.66 billion, net debt is 2.1x adjusted EBITDA against a 4.50x covenant, and the company is simultaneously spending $5 billion buying back stock — so an absorbable settlement is absorbable with room to spare, and only a multi-billion outcome changes the arithmetic. The greater risk is not the cash. It is that a case built on electrophysiology growth guidance keeps that business's credibility in question for the two-to-four years these matters typically run, which is precisely the period over which our base case needs the multiple to normalise. That is why this is Tactical, why the first kill criterion is a legal one, and why the position is sized to be added to rather than defended.

Provenance & disclosures

• Traceability: ZERO knowledge-base claims name Boston Scientific out of 52,021 distilled claims (raw hits 1, case-sensitive entity matches 0, name-level claims 0, discarded 1; breadth 0, claim count 0, net conviction empty). The single hit is discarded outright: michael_levin, 2024-05-03, bullish, conviction 70, horizon principle, skill 1.0, no entities, categories bioelectricity and electrophysiology — "Bioelectricity is underappreciated because it exists only in living cells (unlike DNA/proteins studied dead) and demands interdisciplinary physics/computation training biologists lack." It matched only on the free-text term "electrophysiology", it is a developmental biologist's claim about the state of a scientific discipline, and it names no company, device or market. There is no entity match on BSX, Boston Scientific, Farapulse or Watchman anywhere in the store. No expert in this knowledge base has said anything about Boston Scientific across the six years it covers — a period in which the shares roughly tripled and then halved, the Axonics acquisition closed, pulsed-field ablation became the most-discussed growth story in medical devices, and a securities fraud class action was filed over that same franchise. This is the fourteenth void this programme has found and reported honestly, and it is also a coverage observation worth recording: the store is deep on macro, energy, crypto and AI infrastructure and absent on medical devices. The Buy — Tactical designation is therefore earned on filings and arithmetic alone, with no corroborating expert lane, and that is explicitly one of the four reasons it is Tactical rather than Core.
• Data as-of: fundamentals — income statement, balance sheet, segment and business-unit net sales, organic growth decomposition, the GAAP-to-adjusted bridge and the litigation disclosure through 2026-06-30, all filing-verified from the 10-Q filed 2026-08-03, one day before this dive; annual figures for FY2025, FY2024 and FY2023 from the 10-K filed 2026-02-17, including the debt table, the lease note, the covenant terms and the cash-flow statement · corporate actions from the 8-Ks of 2026-05-18 and 2026-07-27 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873600 = 2026-08-04T20:00:00Z ($49.12, +1.42%; 50-DMA $46.29; 200-DMA $72.69; RSI 82.0; MACD +0.39; beta 0.577) · knowledge-base claims 2026-08-04. Boston Scientific's fiscal year is the calendar year. All figures come from the Synthos vendor data file for BSX or from the SEC filings in the BSX archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2026-02-17 (fiscal 2025 — the source of the debt table showing total debt of $11,436M, the operating-lease note showing $536M of lease liabilities, the credit-agreement covenant terms including the exhausted restructuring-charge exclusion, and the cash-flow statement); 10-Q filed 2026-05-01 (March 2026 quarter); 10-Q filed 2026-08-03 (June 2026 quarter — the source of the organic growth decomposition by business, the balance sheet, the adjusted-EPS bridge and the complete securities class action disclosure); 8-K filed 2026-05-18, disclosing the $2 billion accelerated share repurchase with JPMorgan at a $52.68 reference price, part of a $5 billion authorisation with $3 billion remaining — absent from every vendor field; 8-K filed 2026-07-27, disclosing the 2026 Restructuring Plan approved 2026-07-21 with $700-800M of pre-tax charges by type and a targeted $500M reduction in gross annual pre-tax expense — absent from every vendor field; 8-K filed 2026-07-29 (second-quarter earnings, Item 2.02 — Exhibit 99.1 itself is not present in the extracted text; the quarter's figures come from the 10-Q filed 2026-08-03). All carry preserved [TABLE] statement data.
• Where the filings contradicted or corrected the vendor (detailed in Section 7): the securities class action filed 2026-03-05 and amended 2026-07-20 to add a Section 20A insider-trading count, the $2 billion accelerated share repurchase of 2026-05-18 and the 2026 Restructuring Plan approved 2026-07-21, all absent from every vendor field — with the buyback omission the most consequential, because cf_a's most recent word on capital return is zero repurchases in each of three years; est.ebitdaAvg/ebitAvg, fabricated at exactly 23.196% and 15.006% of revenue in all eight years and additionally impossible, with netIncomeAvg exceeding ebitdaAvg in every forward year (FY2027: net income $5,040M against EBITDA $5,168M and EBIT $3,344M); bal_a.totalDebt of $12,418M against the 10-K's $11,436M, an $982M inflation of which exactly $90M reconciles to the current operating lease liability and $892M does not reconcile to any single filed line, with shortTermDebt ($389M against $299M) and longTermDebt ($11,458M against $11,137M) both individually off; bal_a cash at 2025-12-31 of $2,045M against the filed $1,965M; cf_a FY2023 capitalExpenditure of $800M against the filed $711M, in a row where the adjacent investmentsInPropertyPlantAndEquipment field reports the correct $711M — two fields that should agree, one right and one wrong, in one year of a four-year block; and seg_prod, whose FY2021 row inconsistently adds a "Cardiac Rhythm Management" line absent from adjacent years and whose FY2012 and FY2011 rows use a different seven-line taxonomy, alongside seg_geo rows for FY2012 and FY2011 containing the XBRL placeholder labels "Segment, Geographical, Groups of Countries, Group One" and "Group Two". Where vendor and filing AGREED — recorded, because a clean check is a finding, and BSX has the best enterprise-value construction in this batch: enterpriseValueTTM's $12,085M residual reconciles EXACTLY to the 2026-06-30 balance sheet — current debt obligations $1,709M plus long-term debt $10,915M less cash $539M — using the most recent quarter rather than the annual balance sheet and WITHOUT adding the $536M of operating lease liabilities that inflated totalDebt on five other names in this batch, with the only defect being the omission of $239M of noncontrolling interests (rebuilt $85,334M, 0.28% higher); capitalExpenditure for FY2025 and FY2024 is exactly correct at $876M and $790M against the 10-K's "Purchases of property, plant and equipment and internal use software", making freeCashFlow of $3,658M and the 5.01% recomputed yield sound; and seg_geo is correct and complete for the last eight years, with United States plus Non-US summing exactly to consolidated net sales in every year from FY2018 to FY2025.
• Basis note: analyst estimates are on adjusted diluted EPS, verified against earn_cal, whose epsActual values ($0.86 for Q2 2026, $0.80 for Q1 2026) match the 10-Q's non-GAAP reconciliation exactly. The June-quarter bridge takes GAAP diluted EPS of $0.61 to adjusted $0.86 through amortisation $0.14, acquisition/divestiture $0.05, restructuring $0.02, litigation $0.04, EU Medical Device Regulation $0.00, deferred tax $0.05, less an $83M IEEPA tariff refund of $0.05 that the company excludes as a credit — a 41% adjustment, of which the largest component is intangible amortisation from a decade of acquisitions. Trailing adjusted EPS of $3.21 (15.3x) is built from the four quarterly releases; trailing GAAP EPS of $2.48 (19.8x) is reported alongside. est.ebitdaAvg and est.ebitAvg are rejected outright; all forward valuation uses epsAvg, which verifies to within 0.5% against FY2025 actuals.
• Estimate coverage: 14 analysts on FY2026 adjusted EPS and 16 on FY2027 — the anchor for all three fair values, with an FY2027 range of $3.236 to $3.704, a 14.5% spread — falling to 7 on FY2028 and 2 on FY2029, which is excluded. Revenue coverage is the deepest in this batch at 19, 22, 24 and 23 analysts across FY2026 to FY2029. The FY2027 consensus of 4.4% revenue growth and 3.9% adjusted EPS growth is the lowest forward year of any name in this batch and is the crux of the valuation; this dive states that it cannot distinguish a trough from a waypoint.
• Peer note: the vendor peer set — Abbott, Amgen, Danaher, Gilead, HCA Healthcare, McKesson, Medtronic, Pfizer, Sanofi, Stryker — contains three genuine medical-device comparables (Abbott, Medtronic, Stryker) and seven that are not: three large-cap pharmaceutical companies, a biotechnology company, a hospital operator, a drug distributor and a life-sciences instruments group. Edwards Lifesciences and Johnson & Johnson's MedTech division — the two most direct competitors in the electrophysiology franchise at the centre of both the growth deceleration and the litigation — are absent. No peer-multiple comparison is drawn.
• Fair-value caveat: the $39 / $60 / $82 anchors are multiples of the FY2027 consensus adjusted EPS distribution — 12.1x the low of $3.236, 17.5x the mean of $3.431, and 22.1x the high of $3.704 — cross-checked on EV/EBITDA against a rebuilt enterprise value of $85,334M and against free cash flow. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 15x gives $51.5, which is 4.8% above spot, and 20x gives $68.6, essentially the street's target. The base case REQUIRES MULTIPLE EXPANSION, from 14.3x to roughly 17.5x — this is the fragile leg and it is named as such in Section 5b rather than buried. In every other Buy this house has issued, most of the return was earnings growth; here consensus EPS growth is 3.9% and the re-rating does the work.
• Timing and entry discipline: second-quarter results were released 2026-07-29 and the 10-Q was filed 2026-08-03, one day before this dive; adjusted EPS of $0.86 beat by 3.0%, the sixth consecutive beat in the earnings calendar. The technical entry is the weakest part of this recommendation: RSI 82.0, the price 6.1% above the 50-day average of $46.29, after a 15.2% bounce off the 52-week low of $42.63. The recommendation is therefore explicitly a scaled entry — a 1.0% starter today against a 3% target, with the balance reserved for a retest of $46.29 or $42.63, or for confirmation that Cardiovascular growth has stabilised. The next print is 2026-10-28, 85 days away. The most recent insider filings are dated 2026-07-31 and are both acquisitions.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.